Compare Moderna, Inc. (MRNA) vs Peloton Interactive Inc (PTON) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.

Peloton (PTON) trades at $4.92, up 1.44% on the day, with a bearish technical signal and neutral oscillators. The company reported its first full-year net profit in 2026, with revenue of $2.4B and a net income margin of 2.58%. Recent product launches include a foldable treadmill and AI-powered coaching features, signaling a focus on growth and innovation amid a challenging market.

The outlook remains mixed; analyst consensus is a Buy with a $8.00 price target, but risks include high debt, negative equity, and competitive pressures. Positive cash flow trends and cost-cutting efforts support a turnaround narrative, yet subscriber declines and insider selling warrant caution for investors.